Company Information
Modex Therapeutics Ltd
Av. De Sévelin 18-20
1004 Lausanne
Suisse
+41 21 620 60 00
http://www.modex-t3r.com/
- CEO
- Jaques Essinger
- Investor Relations
- David Jones
Modex Therapeutics Ltd is a biotechnology company with a focus on tissue repair, replacement and regeneration (T3R).
Trading Information
- Sector
- Health Care - 4500
- Regulatory Standard
- New Market
- Security Number
- 1081308
- ISIN
- CH0010813084
- Symbol
- MDXN
- Index member
- SPI, SNMI
Intermediaries
- Listing Agent
- Bank Vontobel AG
- Lead Bank
- Bank Vontobel AG
- Auditor
- Ernst & Young S.A.
Information on the Issue
| Security Details | |
|---|---|
| First Listing | 23.06.2000 |
| Class of Share | Action nominative |
| Nominal Value | 10.00 CHF |
| Total Shares outstanding (post issue; incl. Greenshore - if any) | 1347000 |
| Allocation Details | |
|---|---|
| Primary Shares | 375000 |
| Secondary Shares | 60000 |
| Primary Greenshoe | n/a |
| Secondary Greenshoe | n/a |
| Greenshoe Details | |
|---|---|
| Executed | yes |
| Ex-date | 27.06.2000 |
| Executed number of shares | 60000 |
| First Trading Day Details | |
|---|---|
| First Trading | 23.06.2000 |
| Price Range | 148.00 - 168.00 CHF |
| Issue Price | 168.00 CHF |
| First Open | 202.00 CHF |
| First Close | 201.75 CHF |
| Transaction size in Mio. (incl. executed Greenshoe) | 83.2 CHF |
| Market Capitalisation in Mio. (based on first closing price) | 271.8 CHF |
Financial Statement
| Number of Employees | 21 1999 |
| Net Revenues in Mio. | 0.15 CHF 1999 |
| Net Gain in Mio. | n/a |